Aspirin – a new osteoporosis drug

A study published almost a decade ago made the bold claim that aspirin may be a novel drug for osteoporosis.

However, the study did not get much traction and was in fact mocked by medical professionals since mainstream medicine considered the known anti-estrogenic effects of aspirin to be incompatible with a bone-protective effect. The study below may finally change this attitude as it provides direct evidence from human trials for the benefits of aspirin.

“…The researchers conducted a systematic review and exploratory meta-analysis of observational studies. This study was published in the British Medical Journal. A total of 12 studies were included in the meta-analysis, Electronic searches of MEDLINE and Embase, and a manual search of bibliographies was undertaken for studies published to 28 March 2018. Studies were included if participants were men or women aged ≥18 years; the exposure of interest was aspirin.Risk of bias was assessed using the Joanna Briggs Institute Critical Appraisal Checklists for observational studies. Following are the findings: 1) Data pooled from six studies that included 511 390 people indicated aspirin was associated with a 17% lower odds of any fracture. 2) Aspirin was associated with a higher total hip BMD for women and men. 3) No meta-analyses were undertaken for femoral neck or total body BMD as there were too few studies.”

Author: haidut